The STEP 1 trial is the largest, most-cited dataset on how much weight people actually lose on Wegovy. Here's the full breakdown.
In the STEP 1 trial, Wegovy produced 14.9% average weight loss at 68 weeks, versus 2.4% for placebo. About 86% of participants lost at least 5% of their body weight.
Wilding JPH et al., New England Journal of Medicine, 2021 (STEP 1, NCT03548935). Not medical advice — individual results vary significantly.
These are responder rates from the STEP 1 trial at 68 weeks — the share of participants who reached each weight-loss threshold, not the average. Averages and individual outcomes are different things; a wide range of results is normal.
Starting dose (0.25mg). Appetite changes may be subtle; GI side effects are most common here.
Dose steps up. Many people start noticing steadier appetite reduction and early weight change.
At or near the 2.4mg maintenance dose. This is where most of the cumulative weight loss happens in trial data.
Weight loss tends to level off as the body reaches a new equilibrium at a stable dose.
Starting weight, diet, activity, sleep, and other medications all affect your personal trajectory.
A leveling-off doesn't mean the medication has stopped working — it's the expected pattern in trial data too.
These are separate trials with different designs, timepoints, and participant groups, so the numbers aren't directly interchangeable — but they consistently land in a similar range for Wegovy.
One email at launch · free trial · no credit card